Age (years) |
73.4±5.5 |
74.0±6.5 |
0.60 |
Sex (male) |
26 (52.0%) |
28 (54.9%) |
0.84 |
Race (white) |
50 (100%) |
50 (98.0%) |
1.00 |
Ethnicity (non-Hispanic/Latino) |
50 (100%) |
51 (100%) |
1.00 |
Hypertension |
31 (62.0%) |
35 (68.6%) |
0.48 |
Diabetes |
16 (32.0%) |
22 (44.0%) |
0.30 |
Depression |
16 (32.0%) |
12 (23.5%) |
0.34 |
Heart failure |
11 (22.0%) |
8 (16.0%) |
0.44 |
Renal disease |
8 (16.0%) |
14 (28.0%) |
0.15 |
Atherosclerosis |
6 (12.0%) |
10 (19.6%) |
0.30 |
CAD |
8 (16.0%) |
18 (36.0%) |
0.02 |
Prior MI |
3 (6.0%) |
9 (18.0%) |
0.07 |
Prior revascularization |
1 (2.0%) |
8 (16.0%) |
0.03 |
Prior stroke |
6 (12.0%) |
6 (11.8%) |
0.97 |
Prior TIA |
4 (8.0%) |
4 (8.0%) |
1.00 |
History of vascular disease |
3 (6.0%) |
5 (10.0%) |
0.72 |
AF type, n=67 |
|
|
0.28 |
Paroxysmal |
27 (81.8%) |
32 (94.1%) |
|
Persistent |
4 (12.1%) |
1 (2.9%) |
|
Long-standing persistent |
2 (6.1%) |
1 (2.9%) |
|
Prior ablation |
5 (10.0%) |
4 (8.0%) |
1.00 |
Pacemaker |
6 (12.0%) |
7 (14.0%) |
0.77 |
Defibrillator |
2 (4.0%) |
2 (4.0%) |
1.00 |
History of cancer |
6 (12.0%) |
13 (26.0%) |
0.07 |
Sleep apnea |
16 (32.0%) |
17 (34.0%) |
0.83 |
BMI (kg/m2) |
30.7±9.8 |
29.3±7.8 |
0.44 |
Systolic blood pressure |
131.5±16.3 |
131.6±22.5 |
0.98 |
Diastolic blood pressure |
78.7±12.2 |
76.1±16.9 |
0.38 |
CHA2DS2-VASc Categories, n=100 |
|
|
0.38 |
<1 |
3 (6.0%) |
2 (4.0%) |
|
2-4 |
37 (74.0%) |
32 (64.0%) |
|
>5 |
10 (20.0%) |
16 (32.0%) |
|
ATRIA Bleeding Risk Categories, n=74 |
|
|
0.29 |
<1 |
19 (51.4%) |
15 (40.5%) |
|
2-4 |
15 (40.5%) |
21 (56.8%) |
|
>5 |
3 (8.1%) |
1 (2.7%) |
|
Dabigatran starting dose |
|
|
|
75 mg BID |
3 |
— |
— |
150 mg BID |
44 |
— |
— |
Withdrew before start |
3 |
— |
— |